Evaluation of Rifampicin Resistance in Tuberculosis Patients Co-Infected with HIV/AIDS in Port-Harcourt, Nigeria
DOI:
https://doi.org/10.14738/bjhmr.111.15894Keywords:
Mycobacterium tuberculosis, multi-drug resistance, prevalence, co-infection, anti-retroviral therapyAbstract
Due to insufficient information on the prevalence of rifampicin resistance among people co-infected with TB and HIV/AIDS, this study was aimed at determining the prevalence of rifampicin resistance in HIV/AIDS and tuberculosis (TB) patients attending clinical appointments at the University of Port Harcourt Teaching Hospital (UPTH), Rivers State, Nigeria. A total of 3768 patients, comprising 1906 (58.6%) females and 1862 (49.4%) males, were enrolled in the study. Serial testing algorithms (rapid diagnostic kits) and Genexpert were used to screen for HIV and TB, respectively. The TB result showed that a total of 305 (8.1%), with men being 175 (57.4%) and women being 130 (42.6%), tested positive. Also, 32 patients (0.8%) had HIV and TB co-infections. Among those positive for TB, 11 (3.6%), including 5 (1.6%) men and 6 (2.0%) women, were rifampicin-resistant positive. Of the 32 patients with MTB/HIV co-infection, 3 (9.4%) were rifampicin-resistant, 20 (62.5%) were sensitive, and 9 (28.1%) were indeterminate. Furthermore, of the 32 MTB/HIV co-infected individuals, 27 (84.4%) had HIV 1 mono-infection, none had HIV 2 mono-infection, and 5 (15.6%) had HIV 1 and HIV 2 co-infection. The co-infected patients with HIV 1 and HIV 2 showed signs of rifampicin-resistant tuberculosis (RR-TB). These outcomes suggest that MTB transmission among the populace is linked to co-infection with HIV 1 and HIV 2, as well as rifampicin resistance in TB patients. Therefore, to properly manage both infections and lessen their impact, HIV testing among patients getting MTB treatment is highly encouraged.
References
Chandrasekaran P, Gopalan N, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian Journal of Medical Research. 2011; 134(6): 850–0.
Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione M, et al. The Growing Burden of Tuberculosis. Archives of internal medicine. 2003; 163(9): 1009–9.
Lawn SD, Churchyard GJ. Epidemiology of HIV-associated tuberculosis. Current Opinion in Hiv and Aids. 2009; 4(4): 325–33.
Getaneh T, Negesse A, Dessie G, Desta M. The impact of tuberculosis co infection on virological failure among adults living with HIV in Ethiopia: A systematic review and meta-analysis. Journal of clinical tuberculosis and other mycobacterial diseases. 2022; 27.
Lange C, Alghamdi WA, Alshaer MH, Brighenti S, Diacon AH, DiNardo A, et al. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. Journal of Internal Medicine. 2018; 284(2): 163–88.
Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How Soon after Infection with HIV Does the Risk of Tuberculosis Start to Increase? A Retrospective Cohort Study in South African Gold Miners. The Journal of Infectious Diseases. 2005; 191(2): 150–8.
Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and Challenges for HIV Care in Overlapping HIV and TB Epidemics. JAMA. 2008; 300(4): 423–3.
Getahun H, Gunneberg C, Granich R, Nunn P. HIV Infection–Associated Tuberculosis: The Epidemiology and the Response. Clinical Infectious Diseases. 2010; 50(3): 201–7.
Regazzi M, Cristina A, Villani P, Matteelli A. Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins. Clinical Pharmacokinectics. 2014; 53(6): 489–507.
Gambo A, El-Kamary SS, Alash’le A, Blattner WA, Manhattan C. Demography and the dual epidemics of tuberculosis and HIV: Analysis of cross-sectional data from Sub-Saharan Africa. PLOS ONE. 2018; 13(9): 0191387–7.
Noel EE, Pascal N, Marie PH, Afane-Voundi Y, Coppieters Y. Risk factors for mortality in patients with tuberculosis and HIV in Douala (Cameroon). Médecine et santé tropicales. 2017; 27(3): 286–91.
Burki T. Tuberculosis-resistance, funding, and drugs. Lancet Infectious Diseases 2010; 10: 297-298.
Lawson L, Habib AG, Okobi MI, Idiong D, Olajide I, Emenyonu N. Pilot study on multidrug resistant tuberculosis in Nigeria. Annual African Journal of Medicine. 2010; 9:184-7.
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi AH. The emergence of new forms of totally drug-resistant Tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug resistant strains in Iran. Chest. 2009; 136: 420-5.
Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases. 2012; 54: 579-81.
Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. American Review Respiratory Disease. 1981; 123: 367-71.
Reddy R, Alvarez-Uria G. Molecular Epidemiology of Rifampicin Resistance in Mycobacterium tuberculosis Using the GeneXpert MTB/RIF Assay from a Rural Setting in India. Journal of pathogens [Internet]. 2017; 2017: 1–5.
Blumberg HM, Burman WJ, Chaisson RE. American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America. American Thoracic Society/Centers for Disease Controland Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory Crit Care Med. 2003; 167: 603-62.
Ukwamedua H, Omote V, Etaghene J, Oseji ME, Agwai I, Agbroko H. Rifampicin resistance among notified pulmonary tuberculosis (PTB) cases in South-Southern Nigeria. Heliyon. 2019; 5(7): e02096–6.
Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. American Review Respiratory Disease. 1986; 133:423-30.
Althomsons SP, Cegielski JP. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough. Internal Journal of Tuberculosis and Lung Diseases. 2012; 16:1331–4.
Meyssonnier V, Bui TV, Veziris N, Jarlier V, Robert J. Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis. BMC Infection Disease. 2014; 14:18.
Prach LM, Pascopella L, Barry PM. Rifampin mono-resistant tuberculosis and HIV co-morbidity in California, 1993–2008: a retrospective cohort study. AIDS. 22013; 7:2615-22.
Seung KJ, Gelmanova IE, Peremitin GG. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clinical Infectious Diseases. 2004; 39:1321-8.
Ren DJ. Incidence of HIV and pulmonary tuberculosis co-infection among patients attending the outpatient clinic in a Nigerian hospital [Internet]. Scholar Science Journals. 2015.
World Health Organization. Tuberculosis. Fact sheet. https://www.who.int/news-room/factsheets/detail/tuberculosis. 2012 288
Otokunefor K, Otokunefor TV, Omakwele G. Multi-drug resistant Mycobacterium tuberculosis in Port Harcourt, Nigeria. African journal of laboratory medicine. 2018; 7(2), 805.
Ugwu KO, Agbo MC, Ezeonu IM. Prevalence of tuberculosis, drug-resistant tuberculosis and hiv/tb coinfection in Enugu, Nigeria. African Journal of Infectious Diseases. 2021; 15(2): 24–30.
World Health Organization. Tuberculosis outbreaks in schools: experiences from the Western Pacific Region. Manila, Philippines. World Health Organization Regional Office for the Western Pacific; 2020. License: CCBY-NC-SA 3.0IGO. Retrieved from www.who.com on 14th March, 2022.
World Health Organization. TB-HIV co-infection. WHO Myanmar factsheet special. January 2019.
UNAIDS. Human immunodeficiency virus (HIV) Fact sheet. 2021.
Erhabor O, Jeremiah ZA, Adias TC, Okere C. The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt, Nigeria. HIV/AIDS (Auckland, N.Z.). 2010; 2: 1–5.
Brennan CA, Bodelle P, Coffey R, Devare SG, Golden A, Hackett J, Kaptué L. The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. Journal of Acquired Immune Deficiency Syndromes. 2008; 49(4): 432-439.
Nyombi BM, Kristiansen KI, Bjune G, Müller F, Holm-Hansen C. Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions, Tanzania. AIDS research and human retroviruses. 2008; 24(6): 761-769.
Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, Rayfield MA. (1999). Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS research and human retroviruses. 1999; 15(6): 603-608.
Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PloS one. 2013; 8(5): e64915.
Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Seminars in respiratory and critical care medicine. 2013; 34(1): 32–43.
Nwalozie RM, Agbagwa OE, Mac-Fiberesima G. (A Retrospective Review of Rifampicin-Resistant Mycobacterium tuberculosis between 2015 and 2017 in Port Harcourt, Nigeria. International Journal of Tropical Disease. 2019; 35 (2) 1-6
Audu ES, Gambo MS, Yakubu AA. Rifampicin resistant mycobacterium tuberculosis in Nasarawa State, Nigeria. Nigerian Journal of basic and clinical sciences. 2017; 14(1): 21-25
Ibrahim MM, Isyaka TM, Askira UM, Umar JB, Mustafa A, Isa MA, Mustapha A, Salihu A. Trends in the incidence of Rifampicin-resistant Mycobacterium tuberculosis infection in northeastern Nigeria. Scientific African. 2022; 17: e01341
Onyedum CC, Alobu I, Ukwaja KN. Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis. Public Library of Science ONE. 2017; 12(7): e0180996.
Akinnusi OO, Bello AJ, Adeleye IA, Nutor JJ. Evaluation of HIV infection in febrile patients visiting health centers in Lagos, Nigeria. BMC research notes. 2022; 15(1): 71.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kennedy Tamunokubie Atemie, Helen Ifeoma Udujih, Dennis Chimezie Nwosu, Chizaram Winners Ndubueze, Danagogo Stephenson Lawson
This work is licensed under a Creative Commons Attribution 4.0 International License.
